In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans

Journal of Antimicrobial Chemotherapy

Volumn 41, Issue 1, 1998, Pages 59-65

  Barchiesi, Francesco ^a,b   Di Francesco, Luigi Falconi ^a   Compagnucci, Patrizia ^a   Arzeni, Daniela ^a   Giacometti, Andrea ^a   Scalise, Giorgio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Azienda Ospedaliera Umberto I   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; FLUCONAZOLE; ITRACONAZOLE; TERBINAFINE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG POTENTIATION; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; MINIMUM INHIBITORY CONCENTRATION; MOUTH CAVITY; NONHUMAN; SPECTROPHOTOMETRY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLUCONAZOLE; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; NAPHTHALENES;

EID: 0031908759     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/41.1.59     Document Type: Article

References (23)

1. Graybill, J. R., Burgess, D. S. & Hardin, T. C. (1997). Key issues concerning fungistatic versus fungicidal drugs. European Journal of Clinical Microbiology and Infectious Diseases 16, 42-50.
2. Iwata, K. (1992). Drug resistance in human pathogenic fungi. European Journal of Epidemiology 8, 407-21.
3. Odds, F. C. (1993). Resistance of yeasts to azole-derivative antifungals. Journal of Antimicrobial Chemotherapy 31, 463-71.
4. Warnock, D. W. (1992). Azole drug resistance in Candida species. Journal of Medical Microbiology 37, 225-6.
5. Warnock, D. W., Johnson, E. M., Richardson, M. D. & Vickers, C. F. H. (1983). Modified response to ketoconazole of Candida albicans from a treatment failure. Lancet i, 642-3.
6. Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E. & Saral, R. (1991). Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New England Journal of Medicine 325, 1274-7.
7. Allendoerfer, R., Marquis, A. J., Rinaldi, M. G. & Graybill, J. R. (1991). Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrobial Agents and Chemotherapy 35, 726-9.
8. Franzot, S. P. & Casadevall, A. (1997). Pneumocandin L-743,872 enhances the activity of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrobial Agents and Chemotherapy 41, 331-6.
9. Nguyen, M. H., Barchiesi, F., McGough, D. A., Yu, V. L. & Rinaldi, M. G. (1995). In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrobial Agents and Chemotherapy 39, 1691-5.
10. Polak, A., Scholer, H. J. & Wall, M. (1982). Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. Experimental Chemotherapy 28, 461-79.
11. Balfour, J. A. & Faulds, D. (1992). Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 43, 259-84.
12. Warren, N. G. & Shadomy, H. J. (1991). Yeasts of medical importance. In Manual of Clinical Microbiology, 5th edn (Balows, A., Hausler, W. J., Herrmann, K. L., Isenberg, H. D. and Shadomy, H. J., Eds), pp. 617-29. American Society of Microbiology, Washington, DC.
13. National Committee for Clinical Laboratory Standards. (1995). Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeasts. Tentative Standard. Document M27-T. NCCLS, Way ne, PA.
14. Koneman, E. W., Allen, S. D., Janda, W. M., Schreckenberger, P. C. & Winn, W. C. (1992). Antimicrobial susceptibility testing. In Diagnostic Microbiology, 4th edn (Koneman, E. W., Allen, S. D., Janda, W. M., Schreckenberger, P. C. & Winn, W. C., Eds), pp. 609-68. Lippincott, Philadelphia, PA.
15. Barchiesi, F., Hollis, R. J., McGough, D. A., Scalise, G., Rinaldi, M. G. & Pfaller, M. A. (1995). DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS. Clinical Infectious Diseases 20, 634-40.
16. Boken, D. J., Swindells, S. & Rinaldi, M. G. (1993). Fluconazole-resistant Candida albicans. Clinical Infectious Diseases 17, 1018-21.
17. Johnson, E. M., Warnock, D. W., Luker, J., Porter, S. R. & Scully, C. (1995). Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. Journal of Antimicrobial Chemotherapy 35, 103-14.
18. Redding, S., Smith, J., Farinacci, G., Rinaldi, M., Fothergill, A., Rhine-Chalberg, J. & Pfaller, M. (1994). Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clinical Infectious Diseases 18, 240-2.
19. Barchiesi, F., Del Poeta, M., Morbiducci, V., Ancarani, F. & Scalise, G. (1993). Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans. Mycopathologia 124, 19-25.
20. Pfaller, M. A., Messer, S. A. & Coffmann, S. (1995). Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870. Journal of Clinical Microbiology 33, 1094-7.
21. Lyman, C. A. & Walsh, T. J. (1992). Systemically administered antifungal agents: a review of their clinical pharmacology and therapeutic applications. Drugs 44, 9-35.
22. Yu, V. L., Zuravleff, J. J., Bornholm, J. & Archer, G. (1984). In-vitro synergy testing of triple antibiotic combinations against Staphylococcus epidermidis isolates from patients with endocarditis. Journal of Antimicrobial Chemotherapy 14, 359-66.
23. Moellering, R. C. (1995). Principles of anti-infective therapy. In Principles and Practice of Infectious Diseases (Mandell, G. L., Bennett, J. E. & Dolin, R., Eds), pp. 199-211. Churchill Livingstone, Edinburgh.